Allergen Immunotherapy in the Age of Coronavirus: A Review of Practice Considerations and Evidence to Deliver Uninterrupted Care

 

 

PROGRAM OVERVIEW

In December 2019, the World Health Organization (WHO) received notification of a cluster of patients with pneumonia of unknown cause. By January 23, 2020, the coronavirus causing this outbreak – SARS-CoV-2 – had been identified. The virus has been demonstrated to have person-to-person transmission and appears to have higher infectivity than the other two zoonotic coronaviruses (SARS and MERS), but a lower case-fatality rate. Many of the patients who depend on allergen immunotherapy (AIT) to maintain their quality of life or even prevent life-threatening anaphylaxis may be vulnerable to the most devastating effects of the virus. However, the interruption of AIT may place patients at increased risk of allergic reaction. Given these factors, clinicians may be uncertain as to how to protect their patients while ensuring AIT is delivered appropriately and effectively. This educational activity will equip clinicians with strategies to manage AIT during the COVID-19 pandemic and ensure they are up-to-date on the advances in AIT through review of recent safety and efficacy data from clinical trials and discussion of the impact of COVID-19 on AIT research.

FACULTY

 

David I Bernstein MD
Professor Emeritus of Medicine
Division of Immunology, Allergy and Rheumatology
University of Cincinnati College of Medicine
Medical Director, Bernstein Clinical Research Center LLC
Cincinnati, Ohio

 

Lawrence M. DuBuske, MD
Clinical Professor of Medicine
Division of Allergy and Immunology
Department of Internal Medicine
George Washington University
Washington, District of Columbia
Director, Medical Education & Research Management Services of New England, LLC
Gardner, Massachusetts

 

Russell Settipane, MD
Clinical Professor of Medicine
Department of Internal Medicine
Alpert Medical School
Brown University
Providence, Rhode Island
Director, Allergy & Asthma Center
East Providence, Rhode Island

 

Release date: October 16, 2020
Expiration date: October 16, 2021
Estimated time to complete activity: 1.50 hour(s)

 

TARGET AUDIENCE

This educational initiative is intended for allergists, otolaryngologists, otolaryngic allergists, nurse practitioners, and physician assistants involved in the management of patients receiving allergen immunotherapy.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Integrate current COVID-19 protocols, AIT management strategies, and patient communication approaches to ensure optimal outcomes for patients on AIT
  • Review recent safety and efficacy outcomes from clinical trials involving AIT
  • Describe the impact of COVID-19 on research and guidance from the FDA to address the evolving demands of clinical trials during the pandemic
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of October 16, 2020 through October 16, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 75% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

David Bernstein, MD
Advisory Panel: ALK America, GlaxoSmithKline, Regeneron
Research: Aimmune, ALK-Abello, Inc., Amgen, AstraZeneca, Allergy Therapeutics, Avillion, Biocryst, Boehringer Ingelheim, Cipla, Genentech, GlaxoSmithKline, Gossamer, Leo, Lupin, Menlo, Merck, Mylan, Novartis, Novum, Pearl, Regeneron, Shire, and TEVA
Consultant: Gerson-Lehman, Guidepoint Global, Alpha Insights, HAL, Medacorp, International Isocyanate Institute

Lawrence DuBuske, MD
Consultant: Abionic, ALK-Abello, Inc., Allergy Therapeutics, Sanofi/Regeneron;
Lecture Honorarium: ALK-Abello, Inc., AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi Genzyme
Research Grants: Abionic

Russell Settipane, MD
Speaker’s Bureau: AstraZeneca, Boehringer Ingelheim, Genentech, Grifols, GlaxoSmithKline, Optinose, Pharming, Regeneron, Sanofi, Takeda, Teva
Advisory Boards: Aimmune, ALK-Abello, Inc., AstraZeneca, Biocryst, DBV Technologies, Grifols, GlaxoSmithKline, Pharming, Pfizer, Sanofi/Regeneron, Teva
Research: AstraZeneca, Chiesi, Genentech, GlaxoSmithKline, Merck, Novartis, Regeneron, Stallergenes-Greer

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have financial relationships to products of devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and ALK-Abello do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS

  • Plug-in: Adobe® Flash® Player 10
  • Adobe® Flash® Player 10 plug-in should be downloaded

Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus
For optimal performance, the use of Internet Explorer below 8 is not recommended.
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from ALK-Abello, Inc.

Continue to Pretest